"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 0 | 3 |
| 1997 | 4 | 0 | 4 |
| 1998 | 1 | 1 | 2 |
| 1999 | 2 | 1 | 3 |
| 2000 | 2 | 1 | 3 |
| 2002 | 1 | 3 | 4 |
| 2003 | 3 | 2 | 5 |
| 2004 | 2 | 2 | 4 |
| 2005 | 6 | 2 | 8 |
| 2006 | 0 | 3 | 3 |
| 2007 | 4 | 4 | 8 |
| 2008 | 4 | 4 | 8 |
| 2009 | 5 | 5 | 10 |
| 2010 | 4 | 3 | 7 |
| 2011 | 10 | 5 | 15 |
| 2012 | 6 | 4 | 10 |
| 2013 | 10 | 9 | 19 |
| 2014 | 10 | 4 | 14 |
| 2015 | 10 | 3 | 13 |
| 2016 | 11 | 7 | 18 |
| 2017 | 7 | 4 | 11 |
| 2018 | 7 | 2 | 9 |
| 2019 | 11 | 2 | 13 |
| 2020 | 8 | 2 | 10 |
| 2021 | 4 | 5 | 9 |
| 2022 | 2 | 0 | 2 |
| 2023 | 2 | 0 | 2 |
| 2024 | 0 | 2 | 2 |
| 2025 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Lipidomic profiles associated with treatment related hepatotoxicity in children with acute lymphoblastic leukemia. Support Care Cancer. 2026 Feb 17; 34(3):209.
-
AquIRE reveals the mechanisms of clinically induced RNA damage and the conservation and dynamics of glycoRNAs. Nucleic Acids Res. 2026 Feb 05; 54(4).
-
Maintaining oxaliplatin therapy after hypersensitivity reactions: real-world experience with a desensitisation protocol. Clin Exp Med. 2026 Jan 21; 26(1):118.
-
Evaluating the Antiproliferative Effects of Tri(2-Furyl)- and Triphenylphosphine-Gold(I) Pyridyl- and Pyrimidine-Thiolate Complexes. Biomolecules. 2026 Jan 15; 16(1).
-
Discovery and Characterization of a First-In-Class HCK/BTK PROTAC DFCI-002-06 for the Treatment of MYD88 Mutated B Cell Malignancies. J Med Chem. 2026 Jan 22; 69(2):1119-1134.
-
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations. Eur Urol Focus. 2026 Jan; 12(1):16-18.
-
Design, Optimization, and Development of RIPK1 Degraders with Improved Pharmacokinetic and Pharmacodynamic Properties. J Med Chem. 2025 Nov 13; 68(21):22246-22263.
-
Defining and measuring tolerability in pediatric, adolescent, and young adult oncology: The essential voices. Cancer. 2025 Oct 15; 131 Suppl 2:e35947.
-
Re/99mTc Tricarbonyl Phenformin Complexes Targeting Mitochondria as Pancreatic Cancer Theranostics. J Med Chem. 2025 Nov 13; 68(21):22818-22830.
-
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenstr?m macroglobulinemia. Blood Adv. 2025 Oct 14; 9(19):4842-4847.